Orlando, Fla.-based LensAR Inc. announced the launch of a new U.K. clinical trial, evaluating the company’s laser-based lens softening system in treatment of patients with presbyopia.
The study begins with enrollment of the 1st 30 patients and will expand to more sites by the end of the year, LensAR said.
"The prospect of using the LensAR Laser System for lenticular softening as a potential treatment for presbyopia represents an exciting and immense new market opportunity for LensAR ," CEO Nick Curtis said in prepared remarks. "With our original research, and the associated IP, LensAR is uniquely positioned to serve this huge market segment."
Presbyopia occurs when the lens inside the eye stiffens, often with age, impairing vision and focus on near objects. The condition affects more than a billion patients worldwide, LensAR said.
The device maker also develops cataract surgery systems, and earlier this month raised $87 million in support of its technology, saying it planned to used the funds to advance its global commercial efforts.
